Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R. Crump M, et al. Cancer. 2004 Oct 15;101(8):1835-42. doi: 10.1002/cncr.20587. Cancer. 2004. PMID: 15386331 Free article. Clinical Trial.
A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma.
Crump M, Shepherd L, Lin B. Crump M, et al. Clin Lymphoma. 2005 Jun;6(1):56-60. doi: 10.3816/clm.2005.n.030. Clin Lymphoma. 2005. PMID: 15989710 Clinical Trial. No abstract available.
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI. Crump M, et al. J Clin Oncol. 2008 Jan 1;26(1):37-43. doi: 10.1200/JCO.2007.11.8851. Epub 2007 Nov 19. J Clin Oncol. 2008. PMID: 18025439 Clinical Trial.
Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.
Seshadri T, Kuruvilla J, Crump M, Keating A. Seshadri T, et al. Among authors: crump m. Biol Blood Marrow Transplant. 2008 Mar;14(3):259-67. doi: 10.1016/j.bbmt.2007.11.013. Biol Blood Marrow Transplant. 2008. PMID: 18275892 Free article. Review.
How I treat relapsed and refractory Hodgkin lymphoma.
Kuruvilla J, Keating A, Crump M. Kuruvilla J, et al. Among authors: crump m. Blood. 2011 Apr 21;117(16):4208-17. doi: 10.1182/blood-2010-09-288373. Epub 2011 Jan 24. Blood. 2011. PMID: 21263152 Free article.
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Sehn LH, et al. Among authors: crump m. J Clin Oncol. 2011 Sep 1;29(25):3396-401. doi: 10.1200/JCO.2010.33.6594. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810681 Clinical Trial.
461 results